|
Gene: DCC |
Gene summary for DCC |
Gene summary. |
Gene information | Species | Human | Gene symbol | DCC | Gene ID | 1630 |
Gene name | DCC netrin 1 receptor | |
Gene Alias | CRC18 | |
Cytomap | 18q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P43146 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1630 | DCC | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.29e-02 | 2.02e-01 | -0.059 |
1630 | DCC | HTA11_7469_2000001011 | Human | Colorectum | AD | 5.31e-07 | 7.95e-01 | -0.0124 |
1630 | DCC | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.07e-08 | 6.14e-01 | 0.2585 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190307611 | Liver | Cirrhotic | regulation of protein localization to plasma membrane | 47/4634 | 104/18723 | 4.29e-06 | 7.15e-05 | 47 |
GO:000716312 | Liver | Cirrhotic | establishment or maintenance of cell polarity | 82/4634 | 218/18723 | 1.55e-05 | 2.11e-04 | 82 |
GO:19038285 | Liver | Cirrhotic | negative regulation of cellular protein localization | 48/4634 | 117/18723 | 7.59e-05 | 8.41e-04 | 48 |
GO:00303242 | Liver | Cirrhotic | lung development | 65/4634 | 177/18723 | 2.49e-04 | 2.25e-03 | 65 |
GO:00303232 | Liver | Cirrhotic | respiratory tube development | 66/4634 | 181/18723 | 2.82e-04 | 2.49e-03 | 66 |
GO:00429962 | Liver | Cirrhotic | regulation of Golgi to plasma membrane protein transport | 8/4634 | 10/18723 | 3.84e-04 | 3.19e-03 | 8 |
GO:19030775 | Liver | Cirrhotic | negative regulation of protein localization to plasma membrane | 14/4634 | 24/18723 | 4.64e-04 | 3.75e-03 | 14 |
GO:19054763 | Liver | Cirrhotic | negative regulation of protein localization to membrane | 17/4634 | 32/18723 | 5.24e-04 | 4.14e-03 | 17 |
GO:1902115 | Liver | Cirrhotic | regulation of organelle assembly | 66/4634 | 186/18723 | 6.66e-04 | 5.04e-03 | 66 |
GO:19049502 | Liver | Cirrhotic | negative regulation of establishment of protein localization | 49/4634 | 131/18723 | 8.50e-04 | 6.15e-03 | 49 |
GO:19043764 | Liver | Cirrhotic | negative regulation of protein localization to cell periphery | 14/4634 | 26/18723 | 1.37e-03 | 9.14e-03 | 14 |
GO:0051224 | Liver | Cirrhotic | negative regulation of protein transport | 47/4634 | 127/18723 | 1.39e-03 | 9.27e-03 | 47 |
GO:00015035 | Liver | Cirrhotic | ossification | 127/4634 | 408/18723 | 1.89e-03 | 1.19e-02 | 127 |
GO:01200326 | Liver | Cirrhotic | regulation of plasma membrane bounded cell projection assembly | 63/4634 | 186/18723 | 3.16e-03 | 1.78e-02 | 63 |
GO:003526411 | Liver | Cirrhotic | multicellular organism growth | 47/4634 | 132/18723 | 3.40e-03 | 1.89e-02 | 47 |
GO:00604915 | Liver | Cirrhotic | regulation of cell projection assembly | 63/4634 | 188/18723 | 4.17e-03 | 2.22e-02 | 63 |
GO:00605411 | Liver | Cirrhotic | respiratory system development | 67/4634 | 203/18723 | 4.81e-03 | 2.52e-02 | 67 |
GO:00510514 | Liver | Cirrhotic | negative regulation of transport | 141/4634 | 470/18723 | 5.06e-03 | 2.62e-02 | 141 |
GO:003001012 | Liver | Cirrhotic | establishment of cell polarity | 48/4634 | 143/18723 | 1.09e-02 | 4.79e-02 | 48 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa052101 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa052102 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa052103 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCC | SNV | Missense_Mutation | rs750872111 | c.3257N>T | p.Pro1086Leu | p.P1086L | P43146 | protein_coding | deleterious(0) | possibly_damaging(0.579) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
DCC | SNV | Missense_Mutation | rs767458713 | c.2554G>A | p.Ala852Thr | p.A852T | P43146 | protein_coding | deleterious(0.01) | probably_damaging(0.928) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DCC | SNV | Missense_Mutation | c.1675C>A | p.Gln559Lys | p.Q559K | P43146 | protein_coding | tolerated(0.55) | benign(0.326) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DCC | SNV | Missense_Mutation | rs187939463 | c.2647N>A | p.Val883Ile | p.V883I | P43146 | protein_coding | tolerated(0.12) | benign(0.037) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DCC | SNV | Missense_Mutation | rs750279704 | c.3412N>A | p.Ala1138Thr | p.A1138T | P43146 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DCC | SNV | Missense_Mutation | rs759439297 | c.632N>A | p.Arg211Gln | p.R211Q | P43146 | protein_coding | tolerated(0.15) | possibly_damaging(0.824) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DCC | SNV | Missense_Mutation | rs139280277 | c.2887N>A | p.Val963Ile | p.V963I | P43146 | protein_coding | tolerated(1) | benign(0.01) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
DCC | SNV | Missense_Mutation | rs374199141 | c.4210N>A | p.Glu1404Lys | p.E1404K | P43146 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
DCC | SNV | Missense_Mutation | c.287N>G | p.Ser96Cys | p.S96C | P43146 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1II-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
DCC | SNV | Missense_Mutation | c.704N>C | p.Gly235Ala | p.G235A | P43146 | protein_coding | tolerated(0.18) | benign(0.433) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |